Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Elevation Oncology logo — We are focused on discovering and developing selective cance...

Elevation Oncology

We are focused on discovering and developing selective cancer therapies to treat patients across a range of solid tumors

Founded 2019 United States Boston, United States 5 employees Acquired Total: $232.95M Biopharma, Biotechnology +3

General Information

Company Name Elevation Oncology
Founded Year 2019
Location United States Boston, United States +1
Employees 5
Industries Biopharma, Biotechnology, Health Care +2
Funding Stage Acquired
Social

Get notified when Elevation Oncology moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Elevation Oncology

Elevation Oncology, founded in 2019, is a pioneering oncology company with a focus on discovering and developing selective cancer therapies for patients with various solid tumors and significant unmet medical needs. The company's slogan, "We are focused on discovering and developing selective cancer therapies to treat patients across a range of solid tumors," encapsulates its mission. Elevation Oncology is redefining drug development by identifying innovative, selective cancer therapies that can be tailored to an individual patient’s tumor characteristics. Its lead candidate, EO-3021, is a potential best-in-class antibody drug conjugate (ADC) engineered to target Claudin 18.2, a clinically validated molecular target. This therapy selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. The company is swiftly moving forward with advancing EO-3021 into clinical trials in the United States, focusing on a range of solid tumor indications. Additionally, Elevation Oncology is exploring new partnerships and business development opportunities to expand its innovative oncology pipeline. As of 08 June 2023, Elevation Oncology secured a significant investment of $50.00M in post-IPO equity financing, indicating growing investor interest and confidence in the company's potential to make an impact in the biopharma, biotechnology, health care, and pharmaceutical industries. Based in the United States, Elevation Oncology stands at the forefront of transformative cancer treatment development, poised to address critical medical needs with its pioneering approach.

Taxonomy: oncology research, cancer therapies, solid tumors, antibody drug conjugate, Claudin 18.2, genomic tests, NRG1 fusions, clinical trials, drug development, precision medicine

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition •••••• 1 •••• •••• 01 Jun 2025
Post Ipo Equity •••••• - 01 Jun 2023
Post Ipo Debt •••••• 1
Investor
01 Jul 2022
IPO •••••• - 01 Jun 2021
Series B •••••• 11
Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor Investor
01 Nov 2020

View All 8 Funding Rounds

Elevation Oncology Alternatives & Competitors

Elevation Oncology vs
Phanes Therapeutics, Inc.
Phanes Therapeutics, Inc. United States

At Phanes, we bring innovation that illuminates the path to cure.

Unknown
29 employees
Biotechnology
Elevation Oncology vs
Tarveda Therapeutics
Tarveda Therapeutics United States

To discover, develop and commercialize a new class of potent and selective precision oncology medici...

Unknown
5 employees
Biotechnology, Health Care
Elevation Oncology vs
Solid IO
Solid IO Finland

ENDING THE GUESSWORK IN CANCER CARE | Patient-specific organ-on-chip technology for precision oncolo...

Seed
8 employees
Also compare with: Elevation Oncology vs Tagworks Pharmaceuticals Tagworks Pharmaceuticals

FAQ About Elevation Oncology

We are focused on discovering and developing selective cancer therapies to treat patients across a range of solid tumors
Elevation Oncology was founded in 2019.
Elevation Oncology is headquartered in Boston, United States.
Elevation Oncology operates in the following industries: Biopharma, Biotechnology, Health Care, Life Sciences, Pharmaceutical.
Elevation Oncology has approximately 5 employees.
Elevation Oncology has completed 8 funding rounds, raising a total of $232.95M. The latest funding stage is Acquired.
Top alternatives and competitors to Elevation Oncology include Phanes Therapeutics, Inc., Tarveda Therapeutics, Solid IO, Tagworks Pharmaceuticals, ENB Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Elevation Oncology and Phanes Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Elevation Oncology and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes